Jaguar Health, Inc. (NASDAQ:JAGX)

PRESS RELEASE

published on 06/21/2024 at 22:15, 5 months 1 day ago

Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders
Jaguar Health, Inc. to report pivotal phase 3 OnTarget trial results for cancer supportive care drug crofelemer by July 23, 2024. Investor webcast and podcast interview updates included

Crofelemer Investor Webcast Jaguar Health OnTarget Trial Cancer Supportive Care
BRIEF

published on 06/12/2024 at 14:35, 5 months 10 days ago

Jaguar Health to Announce Pivotal Phase 3 OnTarget Trial Results by July 23, 2024

Crofelemer Investor Webcast Jaguar Health Phase 3 OnTarget Trial Cancer Supportive Care
BRIEF

published on 06/12/2024 at 14:35, 5 months 10 days ago

Jaguar Health annoncera les résultats de l’essai pivot de phase 3 OnTarget d’ici le 23 juillet 2024

Crofelemer Santé Jaguar Webdiffusion Pour Les Investisseurs Soins De Soutien Contre Le Cancer Essai OnTarget De Phase 3
PRESS RELEASE

published on 06/12/2024 at 14:30, 5 months 10 days ago

Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024
Jaguar Health, Inc. to discuss updates on cancer supportive care portfolio in investor webcast, focusing on CTD and oral mucositis. Details on pivotal phase 3 OnTarget trial for crofelemer

Investor Webcast Jaguar Health Inc. Oral Mucositis Cancer Supportive Care CTD
BRIEF

published on 06/07/2024 at 22:20, 5 months 15 days ago

Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Restricted Stock Units Compensation Nasdaq Jaguar Health
BRIEF

published on 06/07/2024 at 22:20, 5 months 15 days ago

Jaguar Health annonce une nouvelle subvention d'incitation aux employés en vertu de la règle d'inscription au Nasdaq 5635(c)(4)

Compensation Nasdaq Unités D'actions Restreintes Santé Jaguar
PRESS RELEASE

published on 06/07/2024 at 22:15, 5 months 15 days ago

Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jaguar Health, Inc. granted 1,111 RSUs to a new employee, subject to one-year vesting. The RSUs were approved by the Compensation Committee

Restricted Stock Units Employee Benefits Jaguar Health Inc. RSUs Compensation Committee
BRIEF

published on 05/29/2024 at 14:35, 5 months 24 days ago

Jaguar Health conclut un accord de licence pour un médicament botanique candidat contre la schizophrénie

Magdalena Biosciences Schizophrénie Santé Jaguar Accord De Licence Drogue Botanique
BRIEF

published on 05/29/2024 at 14:35, 5 months 24 days ago

Jaguar Health Executes Out-License Deal for Botanical Drug Candidate for Schizophrenia

Jaguar Health Magdalena Biosciences Schizophrenia Botanical Drug Out-License Deal
PRESS RELEASE

published on 05/29/2024 at 14:30, 5 months 24 days ago

Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia
Jaguar announces expansion of out-licensing agreement with Magdalena Biosciences for Botanical Drug Candidate targeting schizophrenia market. Company to present at Lytham Partners Spring 2024 Investor Conference

Jaguar Health Magdalena Biosciences Lytham Partners Spring 2024 Investor Conference Out-licensing Agreement Schizophrenia Market

Published on 11/22/2024 at 22:30, 17 minutes ago

Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.
Published on 11/22/2024 at 18:45, 4 hours 2 minutes ago

CORRECTING and REPLACING the Not-So-Secret Lives of REAL "Mormon" Wives - the Eye-Opening New Book From Cedar Fort Publishing & Media - is Now Available for Purchase, Just in Time for Christmas
Published on 11/22/2024 at 16:00, 6 hours 47 minutes ago

Manimal Tales Unveils Two New Personalized Christmas-Themed Books to Spread Holiday Magic and Joy!
Published on 11/22/2024 at 15:55, 6 hours 52 minutes ago

Independent Proxy Advisory Firm ISS Recommends Signal Gold Shareholders Vote for Arrangement Resolution and Private Placement Resolution
Published on 11/22/2024 at 15:15, 7 hours 32 minutes ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

View all ACCESSWIRE

Published on 11/22/2024 at 18:14, 4 hours 32 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 18:00, 4 hours 46 minutes ago

Holding(s) in Company
Published on 11/22/2024 at 17:53, 4 hours 53 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 5 hours 51 minutes ago

EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 6 hours 46 minutes ago

Proposed cancellation of admission to trading

View all EQS

Published on 11/22/2024 at 17:45, 5 hours 2 minutes ago

IMMERSION : RFA 2023/2024
Published on 11/22/2024 at 16:15, 6 hours 31 minutes ago

NRJ GROUP - Le Conseil d'Etat rejette le recours de NRJ 12 et NRJ GROUP
Published on 11/22/2024 at 14:35, 8 hours 11 minutes ago

Communiqué de presse Thales
Published on 11/22/2024 at 14:35, 8 hours 11 minutes ago

Thales Press release
Published on 11/21/2024 at 06:58, 1 day 15 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio

View all LES ECHOS COMFI WIRE

News